Cubist Systematic Strategies’s Cytek Biosciences CTKB Stock Holding History

Cubist Systematic Strategies’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$543K	Buy	156,359 +59,515	+61%	+$223K	﹤0.01%	2241
2025 Q2	$329K	Buy	96,844 +39,431	+69%	+$131K	﹤0.01%	2432
2025 Q1	$230K	Sell	57,413 -59,211	-51%	-$307K	﹤0.01%	2472
2024 Q4	$757K	Buy	+116,624	New	+$695K	﹤0.01%	1962
2023 Q4	–	Sell	-14,995	Closed	-$82.8K	–	3680
2023 Q3	$82.8K	Buy	+14,995	New	+$120K	﹤0.01%	2967
2023 Q2	–	Sell	-35,172	Closed	-$323K	–	3641
2023 Q1	$323K	Sell	35,172 -55,268	-61%	-$594K	﹤0.01%	2942
2022 Q4	$923K	Buy	90,440 +46,074	+104%	+$619K	0.01%	2524
2022 Q3	$653K	Sell	44,366 -39,758	-47%	-$516K	﹤0.01%	2961
2022 Q2	$903K	Sell	84,124 -151,509	-64%	-$1.51M	0.01%	2565
2022 Q1	$2.54M	Buy	+235,633	New	+$3.18M	0.02%	1284
2021 Q4	–	Sell	-8,600	Closed	-$184K	–	3488
2021 Q3	$184K	Buy	+8,600	New	+$202K	﹤0.01%	2606

Other funds holding CTKB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cubist Systematic Strategies's CTKB Position: Q3 2025 in Review

Cubist Systematic Strategies increased its Cytek Biosciences (CTKB) stake by 61% in Q3 2025, buying an estimated $223K and bringing the position to 156,359 shares worth $543K. The position accounts for ﹤0.01% of the portfolio, ranked #2241.

Cubist Systematic Strategies first reported a position in CTKB in Q3 2021 and has held it in 11 quarters since. The position peaked at $2.54M in Q1 2022. 153 funds tracked by Wall St. Rank hold CTKB as of Q3 2025.

Cubist Systematic Strategies held 156,359 shares of Cytek Biosciences worth $543K as of Q3 2025.
Cubist Systematic Strategies bought 59,515 Cytek Biosciences shares in Q3 2025, an estimated $223K.
Cytek Biosciences made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2241 holding.
Cubist Systematic Strategies first reported a position in Cytek Biosciences in Q3 2021 and has held it in 11 quarters since.
Cubist Systematic Strategies's Cytek Biosciences position peaked at $2.54M in Q1 2022.
153 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.